Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice

Antioxidants and Redox Signaling

Volumn 23, Issue 6, 2015, Pages 550-564

  Rocha, Emily M ^a   Smith, Gaynor A ^a   Park, Eric ^b   Cao, Hongmei ^b   Graham, Anne Renee ^b   Brown, Eilish ^b   McLean, Jesse R ^a   Hayes, Melissa A ^a   Beagan, Jonathan ^a   Izen, Sarah C ^a   Perez Torres, Eduardo ^a   Hallett, Penelope J ^a   Isacson, Ole ^a  

^a MCLEAN HOSPITAL   (United States)

^b SHIRE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ALPHA TUBULIN; CATHEPSIN D; COMPLEMENT COMPONENT C1Q; CONDURITOL BETA EPOXIDE; CYTOSKELETON PROTEIN; DYNACTIN; DYNEIN ADENOSINE TRIPHOSPHATASE; EPOXIDE; FLUORESCENT DYE; GLUCOSYLCERAMIDASE; POSTSYNAPTIC DENSITY PROTEIN 95; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; CONDURITOL EPOXIDE; INOSITOL; LYSOSOMAL PROTEINS; PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; BRAIN HOMOGENATE; CELL LOSS; COMPARATIVE STUDY; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; IN VIVO STUDY; MALE; MICROGLIA; MOTOR CORTEX; MOUSE; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OPTICAL DENSITY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN CORTEX; CHEMICALLY INDUCED; COMPLEMENT ACTIVATION; ENZYMOLOGY; METABOLISM; PARKINSON DISEASE; PATHOLOGY; PHYSIOLOGY; PROTEINOSIS; SYNAPTIC TRANSMISSION;

MUS;

ALPHA-SYNUCLEIN; ANIMALS; AUTOPHAGY; AXONAL TRANSPORT; CEREBRAL CORTEX; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; GLUCOSYLCERAMIDASE; INOSITOL; MALE; MICE; MICROGLIA; PARKINSON DISEASE, SECONDARY; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEINS; SYNAPTIC TRANSMISSION;

EID: 84939795706     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2015.6307     Document Type: Article

References (67)

1. Ahmed I, Liang Y, Schools S, Dawson VL, Dawson TM, and Savitt JM. Development and characterization of a new Parkinson's disease model resulting from impaired autophagy. J Neurosci 32: 16503-16509, 2012.
2. Aji BM, Medley G, O'Driscoll K, Larner AJ, and Alusi SH. Perry syndrome: a disorder to consider in the differential diagnosis of Parkinsonism. J Neurol Sci 330: 117-118, 2013.
3. Asselta R, Rimoldi V, Siri C, Cilia R, Guella I, Tesei S, Solda G, Pezzoli G, Duga S, and Goldwurm S. Glucocerebrosidase mutations in primary parkinsonism. Parkinsonism Relat Disord 20: 1215-1220, 2014.
4. Bialas AR and Stevens B. TGF-beta signaling regulates neuronal C1q expression and developmental synaptic refinement. Nat Neurosci 16: 1773-1782, 2013.
5. Braunstein KE, Eschbach J, Rona-Voros K, Soylu R, Mikrouli E, Larmet Y, Rene F, Gonzalez De Aguilar JL, Loeffler JP, Muller HP, Bucher S, Kaulisch T, Niessen HG, Tillmanns J, Fischer K, Schwalenstocker B, Kassubek J, Pichler B, Stiller D, Petersen A, Ludolph AC, and Dupuis L. A point mutation in the dynein heavy chain gene leads to striatal atrophy and compromises neurite outgrowth of striatal neurons. Hum Mol Genet 19: 4385-4398, 2010.
6. Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, and Sudhof TC. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123: 383-396, 2005.
7. Chen L, Jin J, Davis J, Zhou Y, Wang Y, Liu J, Lockhart PJ, and Zhang J. Oligomeric alpha-synuclein inhibits tubulin polymerization. Biochem Biophys Res Commun 356: 548-553, 2007.
8. Choubey V, Safiulina D, Vaarmann A, Cagalinec M, Wareski P, Kuum M, Zharkovsky A, and Kaasik A. Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem 286: 10814-10824, 2011.
9. Chung CY, Koprich JB, Siddiqi H, and Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci 29: 3365-3373, 2009.
10. Cuervo AM and Dice JF. A receptor for the selective uptake and degradation of proteins by lysosomes. Science 273: 501-503, 1996.
11. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, and Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305: 1292-1295, 2004.
12. Cullen V, Lindfors M, Ng J, Paetau A, Swinton E, Kolodziej P, Boston H, Saftig P, Woulfe J, Feany MB, Myllykangas L, Schlossmacher MG, and Tyynela J. Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Mol Brain 2: 5, 2009.
13. Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J, and Bjorklund A. TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity. Proc Natl Acad Sci U S A 110: E1817-E1826, 2013.
14. Dehay B, Bove J, Rodriguez-Muela N, Perier C, Recasens A, Boya P, and Vila M. Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci 30: 12535-12544, 2010.
15. Deleidi M, Hallett PJ, Koprich JB, Chung CY, and Isacson O. The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration. J Neurosci 30: 16091-16101, 2010.
16. Enquist IB, Lo Bianco C, Ooka A, Nilsson E, Mansson JE, Ehinger M, Richter J, Brady RO, Kirik D, and Karlsson S. Murine models of acute neuronopathic Gaucher disease. Proc Natl Acad Sci U S A 104: 17483-17488, 2007.
17. Farrer MJ, Hulihan MM, Kachergus JM, Dachsel JC, Stoessl AJ, Grantier LL, Calne S, Calne DB, Lechevalier B, Chapon F, Tsuboi Y, Yamada T, Gutmann L, Elibol B, Bhatia KP, Wider C, Vilarino-Guell C, Ross OA, Brown LA, Castanedes-Casey M, Dickson DW, and Wszolek ZK. DCTN1 mutations in Perry syndrome. Nat Genet 41: 163-165, 2009.
18. Garcia-Reitbock P, Anichtchik O, Bellucci A, Iovino M, Ballini C, Fineberg E, Ghetti B, Della Corte L, Spano P, Tofaris GK, Goedert M, and Spillantini MG. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain 133: 2032-2044, 2010.
19. Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, Wood NW, and Schapira AH. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 72: 455-463, 2012.
20. Ginns EI, Mak SK, Ko N, Karlgren J, Akbarian S, Chou VP, Guo Y, Lim A, Samuelsson S, LaMarca ML, Vazquez-DeRose J, and Manning-Bog AB. Neuroinflammation and alpha-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction. Mol Genet Metab 111: 152-162, 2014.
21. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, and Sidransky E. Parkinsonism among Gaucher disease carriers. J Med Genet 41: 937-940, 2004.
22. Grabowski GA. Gaucher disease and other storage disorders. Hematology Am Soc Hematol Educ Program 2012: 13-18, 2012.
23. Halperin A, Elstein D, and Zimran A. Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol Dis 36: 426-428, 2006.
24. Hasilik A and Neufeld EF. Biosynthesis of lysosomal enzymes in fibroblasts. Phosphorylation of mannose residues. J Biol Chem 255: 4946-4950, 1980.
25. Ho MW, Seck J, Schmidt D, Veath ML, Johnson W, Brady RO, and O'Brien JS. Adult Gaucher's disease: kindred studies and demonstration of a deficiency of acid betaglucosidase in cultured fibroblasts. Am J Hum Genet 24: 37-45, 1972.
26. Hruska KS, LaMarca ME, Scott CR, and Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 29: 567-583, 2008.
27. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8: 445-544, 2012.
28. Koga H and Cuervo AM. Chaperone-mediated autophagy dysfunction in the pathogenesis of neurodegeneration. Neurobiol Dis 43: 29-37, 2011.
29. Komatsu M, Kominami E, and Tanaka K. Autophagy and neurodegeneration. Autophagy 2: 315-317, 2006.
30. Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, Yoshimori T, Ohsumi Y, Tokuhisa T, and Mizushima N. The role of autophagy during the early neonatal starvation period. Nature 432: 1032-1036, 2004.
31. Lees AJ, Hardy J, and Revesz T. Parkinson's disease. Lancet 373: 2055-2066, 2009.
32. Machaczka M, Rucinska M, Skotnicki AB, and Jurczak W. Parkinson's syndrome preceding clinical manifestation of Gaucher's disease. Am J Hematol 61: 216-217, 1999.
33. Maday S, Wallace KE, and Holzbaur EL. Autophagosomes initiate distally and mature during transport toward the cell soma in primary neurons. J Cell Biol 196: 407-417, 2012.
34. Mak SK, McCormack AL, Manning-Bog AB, Cuervo AM, and Di Monte DA. Lysosomal degradation of alphasynuclein in vivo. J Biol Chem 285: 13621-13629, 2010.
35. Martinez-Vicente M, Sovak G, and Cuervo AM. Protein degradation and aging. Exp Gerontol 40: 622-633, 2005.
36. Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, and Krainc D. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146: 37-52, 2011.
37. McCann H, Stevens CH, Cartwright H, and Halliday GM. alpha-Synucleinopathy phenotypes. Parkinsonism Relat Disord 20 Suppl 1: S62-S67, 2014.
38. McCormack AL, Mak SK, and Di Monte DA. Increased alpha-synuclein phosphorylation and nitration in the aging primate substantia nigra. Cell Death Dis 3: e315, 2012.
39. Montfort M, Chabas A, Vilageliu L, and Grinberg D. Functional analysis of 13 GBA mutant alleles identified in Gaucher disease patients: pathogenic changes and "modifier" polymorphisms. Hum Mutat 23: 567-575, 2004.
40. Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim WS, Sidransky E, Cooper A, Garner B, and Halliday GM. Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease. Brain 137: 834-848, 2014.
41. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, and Edwards RH. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65: 66-79, 2010.
42. Neudorfer O, Giladi N, Elstein D, Abrahamov A, Turezkite T, Aghai E, Reches A, Bembi B, and Zimran A. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 89: 691-694, 1996.
43. Neumann J, Bras J, Deas E, O'Sullivan SS, Parkkinen L, Lachmann RH, Li A, Holton J, Guerreiro R, Paudel R, Segarane B, Singleton A, Lees A, Hardy J, Houlden H, Revesz T, and Wood NW. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 132: 1783-1794, 2009.
44. Orenstein SJ, Kuo SH, Tasset I, Arias E, Koga H, Fernandez-Carasa I, Cortes E, Honig LS, Dauer W, Consiglio A, Raya A, Sulzer D, and Cuervo AM. Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci 16: 394-406, 2013.
45. Osellame LD, Rahim AA, Hargreaves IP, Gegg ME, Richard-Londt A, Brandner S, Waddington SN, Schapira AH, and Duchen MR. Mitochondria and quality control defects in a mouse model of Gaucher disease-links to Parkinson's disease. Cell Metab 17: 941-953, 2013.
46. Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Mann E, Floeter MK, Bidus K, Drayna D, Oh SJ, Brown RH, Jr., Ludlow CL, and Fischbeck KH. Mutant dynactin in motor neuron disease. Nat Genet 33: 455-456, 2003.
47. Rocha EM, Smith GA, Park E, Cao H, Brown EJ, Hallett PJ, and Isacson O. Progressive decline of glucocerebrosidase in aging and Parkinson's disease. Ann Clin Transl Neurol 2: 433-438, 2015.
48. Sardi SP, Clarke J, Kinnecom C, Tamsett TJ, Li L, Stanek LM, Passini MA, Grabowski GA, Schlossmacher MG, Sidman RL, Cheng SH, and Shihabuddin LS. CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucherrelated synucleinopathy. Proc Natl Acad Sci U S A 108: 12101-12106, 2011.
49. Sardi SP, Clarke J, Viel C, Chan M, Tamsett TJ, Treleaven CM, Bu J, Sweet L, Passini MA, Dodge JC, Yu WH, Sidman RL, Cheng SH, and Shihabuddin LS. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc Natl Acad Sci U S A 110: 3537-3542, 2013.
50. Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA, Di Malta C, Donaudy F, Embrione V, Polishchuk RS, Banfi S, Parenti G, Cattaneo E, and Ballabio A. A gene network regulating lysosomal biogenesis and function. Science 325: 473-477, 2009.
51. Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff RM, Greenberg ME, Barres BA, and Stevens B. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74: 691-705, 2012.
52. Settembre C and Ballabio A. TFEB regulates autophagy: an integrated coordination of cellular degradation and recycling processes. Autophagy 7: 1379-1381, 2011.
53. Sidransky E and Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol 11: 986-998, 2012.
54. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, Chen CM, Clark LN, Condroyer C, De Marco EV, Durr A, Eblan MJ, Fahn S, Farrer MJ, Fung HC, Gan-Or Z, Gasser T, Gershoni-Baruch R, Giladi N, Griffith A, Gurevich T, Januario C, Kropp P, Lang AE, Lee-Chen GJ, Lesage S, Marder K, Mata IF, Mirelman A, Mitsui J, Mizuta I, Nicoletti G, Oliveira C, Ottman R, Orr-Urtreger A, Pereira LV, Quattrone A, Rogaeva E, Rolfs A, Rosenbaum H, Rozenberg R, Samii A, Samaddar T, Schulte C, Sharma M, Singleton A, Spitz M, Tan EK, Tayebi N, Toda T, Troiano AR, Tsuji S, Wittstock M, Wolfsberg TG, Wu YR, Zabetian CP, Zhao Y, and Ziegler SG. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 361: 1651-1661, 2009.
55. Sillence DJ. Glucosylceramide modulates endolysosomal pH in Gaucher disease. Mol Genet Metab 109: 194-200, 2013.
56. Sillence DJ, Puri V, Marks DL, Butters TD, Dwek RA, Pagano RE, and Platt FM. Glucosylceramide modulates membrane traffic along the endocytic pathway. J Lipid Res 43: 1837-1845, 2002.
57. Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B, Sher A, Litke AM, Lambris JD, Smith SJ, John SW, and Barres BA. The classical complement cascade mediates CNS synapse elimination. Cell 131: 1164-1178, 2007.
58. Tayebi N, Callahan M, Madike V, Stubblefield BK, Orvisky E, Krasnewich D, Fillano JJ, and Sidransky E. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 73: 313-321, 2001.
59. Tayebi N, Walker J, Stubblefield B, Orvisky E, LaMarca ME, Wong K, Rosenbaum H, Schiffmann R, Bembi B, and Sidransky E. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 79: 104-109, 2003.
60. Tofaris GK, Kim HT, Hourez R, Jung JW, Kim KP, and Goldberg AL. Ubiquitin ligase Nedd4 promotes alphasynuclein degradation by the endosomal-lysosomal pathway. Proc Natl Acad Sci U S A 108: 17004-17009, 2011.
61. Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, Kramer P, Woltjer R, Kukull W, Nelson PT, Jicha GA, Neltner JH, Galasko D, Masliah E, Trojanowski JQ, Schellenberg GD, Yearout D, Huston H, Fritts-Penniman A, Mata IF, Wan JY, Edwards KL, Montine TJ, and Zabetian CP. GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology 79: 1944-1950, 2012.
62. Turner BM and Hirschhorn K. Properties of beta-glucosidase in cultured skin fibroblasts from controls and patients with Gaucher disease. Am J Hum Genet 30: 346-358, 1978.
63. Watanabe Y, Tatebe H, Taguchi K, Endo Y, Tokuda T, Mizuno T, Nakagawa M, and Tanaka M. p62/SQSTM1-dependent autophagy of Lewy body-like alpha-synuclein inclusions. PLoS One 7: e52868, 2012.
64. Winslow AR, Chen CW, Corrochano S, Acevedo-Arozena A, Gordon DE, Peden AA, Lichtenberg M, Menzies FM, Ravikumar B, Imarisio S, Brown S, O'Kane CJ, and Rubinsztein DC. alpha-Synuclein impairs macroautophagy: implications for Parkinson's disease. J Cell Biol 190: 1023-1037, 2010.
65. Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK, Morrison A, Lwin A, Colegial C, Allman JM, and Schiffmann R. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 82: 192-207, 2004.
66. Xilouri M, Brekk OR, Kirik D, and Stefanis L. LAMP2A as a therapeutic target in Parkinson disease. Autophagy 9: 2166-2168, 2013.
67. Xu YH, Reboulet R, Quinn B, Huelsken J, Witte D, and Grabowski GA. Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid betaglucosidase residual activity levels. Mol Genet Metab 94: 190-203, 2008.